UNI-MB - logo
UMNIK - logo
 

Search results

Basic search    Expert search   

Currently you are NOT authorised to access e-resources UM. For full access, REGISTER.

1
hits: 4
1.
  • Nivolumab treatment for oes... Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
    Kudo, Toshihiro, PhD; Hamamoto, Yasuo, Dr; Kato, Ken, PhD ... The lancet oncology, 05/2017, Volume: 18, Issue: 5
    Journal Article
    Peer reviewed

    Summary Background Nivolumab is a human monoclonal IgG4 antibody that inhibits programmed cell death protein 1 (PD-1) expressed on activated T cells. We investigated the safety and activity of ...
Full text
2.
  • Trastuzumab in combination ... Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
    Bang, Yung-Jue, Prof; Van Cutsem, Eric, Prof; Feyereislova, Andrea, MD ... The Lancet (British edition), 08/2010, Volume: 376, Issue: 9742
    Journal Article
    Peer reviewed

    Summary Background Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2; also known as ERBB2), was investigated in combination with chemotherapy for first-line ...
Full text
3.
  • Leucovorin, fluorouracil, a... Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial
    Yamada, Yasuhide, Dr; Takahari, Daisuke, MD; Matsumoto, Hiroshi, MD ... The lancet oncology, 12/2013, Volume: 14, Issue: 13
    Journal Article
    Peer reviewed

    Summary Background Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic colorectal cancer. We aimed to establish ...
Full text
4.
  • Irinotecan plus S-1 (IRIS) ... Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)
    Muro, Kei, Dr; Boku, Narikazu, MD; Shimada, Yasuhiro, MD ... The lancet oncology, 09/2010, Volume: 11, Issue: 9
    Journal Article
    Peer reviewed

    Summary Background Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line chemotherapy for metastatic colorectal cancer. ...
Full text

Load filters